医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meridian Opens a New Office in Beijing, China

2015年01月10日 AM02:18
このエントリーをはてなブックマークに追加


 

CINCINNATI

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) has opened a new office in Beijing, China. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) on the 15th floor in the New China Life Insurance (NCI) Tower Center, in the heart of the central business district (CBD) of Beijing.

Over the years, Meridian has established close relationships with major IVD companies in China by providing high quality and competitive antigens, antibodies, and blockers for in vitro commercial assays. Meridian’s commitment and support to IVD customers in China will be greatly enhanced with local representation.

Lourdes Weltzien, Ph.D., Vice President and General Manager of Meridian Life Science, Inc. stated, “We are excited to open our office in Beijing and bring local support and representation to our important customers in China. We have been delighted to build important and close working relationships with our Chinese customers over the past several years. Now, we are even more excited to demonstrate our increased commitment to our Chinese customers by adding local resources to better service their needs for high quality life science products. Our business in China is growing rapidly and we are committed to continue our investments in such an important market.”

ABOUT MERIDIAN BIOSCIENCE, INC.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

ADDITIONAL INFORMATION

For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, rick.eberly@meridianbioscience.com

CONTACT

Meridian Bioscience, Inc.
Richard L. Eberly, 513-271-3700
rick.eberly@meridianbioscience.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表